FINER, NCT04650581: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor |
|
|
| Active, not recruiting | 3 | 250 | Canada, RoW | Ipatasertib, Fulvestrant, Placebo | Canadian Cancer Trials Group, Hoffmann-La Roche | Breast Cancer | 12/24 | 12/26 | | |
